Literature DB >> 6396192

Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67.

J Gerdes, F Dallenbach, K Lennert, H Lemke, H Stein.   

Abstract

The proportion of proliferating cells in malignant non-Hodgkin's lymphomas (NHL) was determined in situ by immunostaining with the monoclonal antibody Ki-67, which reacts with a nuclear antigen that is present only in proliferating cells. A highly significant correlation could be demonstrated between the proportion of Ki-67 positive cells and the classification into high and low-grade NHL according to the Kiel classification. 93.8 per cent of high-grade and 88.5 per cent of low-grade malignancies were correctly allocated to these groups using the percentage of Ki-67 positive cells as discriminant parameter. On the basis of the medians, the degree of proliferation also paralleled the succession of entities within the Kiel classification. Within most of these different entities, however, the ranges of Ki-67 positive cells varied considerably, indicating that the growth fractions within these groups are rather heterogeneous. Thus it might be useful to determine the growth fraction of each individual case of NHL, because this might be of prognostic value.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6396192     DOI: 10.1002/hon.2900020406

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  65 in total

1.  An Evaluation of DNA Polymerase alpha as a Prognostic Predictor in Early Breast Cancers Smaller than 2 cm.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

2.  Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer.

Authors:  Aleksandra M Urbanska; Emmanouil D Karagiannis; Gonzalo Guajardo; Robert S Langer; Daniel G Anderson
Journal:  Biomaterials       Date:  2012-04-01       Impact factor: 12.479

3.  Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67.

Authors:  J Gerdes; L Li; C Schlueter; M Duchrow; C Wohlenberg; C Gerlach; I Stahmer; S Kloth; E Brandt; H D Flad
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

Review 4.  Proliferation indices in malignant lymphomas.

Authors:  J Crocker
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

5.  Demonstration of estrogen and progesterone receptors as well as Ki-67 and p-145 antigens in single tumor cells from blood and pleural effusions using a slide assay.

Authors:  F W Hirsch; P Deibert; H Busch; G W Löhr; K J Bross
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

6.  Characterisation of normal peripheral blood cells in cycle identified by monoclonal antibody Ki-67.

Authors:  I Cordone; E Matutes; D Catovsky
Journal:  J Clin Pathol       Date:  1992-03       Impact factor: 3.411

7.  Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen.

Authors:  H Kreipe; H H Wacker; H J Heidebrecht; K Haas; M Hauberg; M Tiemann; R Parwaresch
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

8.  Platelet-derived growth factor promotes repair of chronically demyelinated white matter.

Authors:  Adam C Vana; Nicole C Flint; Norah E Harwood; Tuan Q Le; Marcus Fruttiger; Regina C Armstrong
Journal:  J Neuropathol Exp Neurol       Date:  2007-11       Impact factor: 3.685

9.  Proliferative potential of meningiomas determined with the monoclonal antibody Ki-67.

Authors:  W Roggendorf; T Schuster; J Peiffer
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

10.  Proliferation in non-Hodgkin's lymphoma: a comparison of Ki-67 staining on fine needle aspiration and cryostat sections.

Authors:  D C Brown; K C Gatter; D Y Mason
Journal:  J Clin Pathol       Date:  1990-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.